Breaking News

Merck Serono, Quintiles in Clinical Services Pact

May 15, 2013

Will integrate expertise to optimize productivity

Merck Serono and Quintiles have entered a five-year clinical development agreement to create a comprehensive process that integrates the expertise from both organizations with the goal of optimizing productivity in the design and execution of studies.
Quintiles will be the sole primary provider of Merck Serono’s outsourced clinical development services for its global clinical programs, providing Merck Serono with expanded global reach to implement development programs around the world. Merck Serono will lead the strategy of its clinical development programs, with Quintiles directing clinical trial planning and execution. Quintiles will also contribute to Merck Serono’s future clinical trial design activities through optimized clinical trial design and execution strategies, and will collaborate in strategic decision-making processes affecting the development of Merck Serono’s portfolio.
“By combining the strengths of Merck Serono and Quintiles, we are creating a new model in clinical development that will unlock the knowledge and insights of both companies,” said Annalisa Jenkins, executive vice president and head of Global Development and Medical at Merck Serono. “This is an innovative and unique collaboration that will help to translate the highest-quality science into efficiency and agility throughout our clinical trials, while enhancing our competitive position in an increasingly challenging environment of clinical drug development.”
“This agreement is built upon a long-standing commitment to trust and transparency between our two organizations, and I’m confident it will only be enhanced by this innovative relationship,” said Tom Pike, chief executive officer, Quintiles. “We are excited about the opportunities this collaboration provides as we work with Merck Serono in a new and innovative manner that leverages the best of our combined capabilities. We view this as a key step forward not only for our two companies, but for the way the industry approaches the development of new therapies for the patients we ultimately serve.”
  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems